(Total Views: 571)
Posted On: 08/20/2021 12:28:22 PM
Post# of 148903
Biden has ruled out FDA's Woodcock as nominee
Acting FDA Commissioner Janet Woodcock has reportedly been ruled out as a nominee for the agency's permanent position, according to sources familiar with the matter. Controversy over the FDA's approval of Biogen's Alzheimer's disease drug Aduhelm may have affected Woodcock's prospects of being nominated as permanent FDA chief.
" Woodcock, 72, who has been at the FDA for 35 years, declined to comment.
"The Department of Health and Human Services Office of Inspector General also said earlier this month it would examine the FDA’s use of an approval process intended to grant speedier access to experimental medicines, which the agency used for Aduhelm.
The office said as part of the probe it would look into concerns raised about contacts between FDA and Biogen officials before the clearance of Aduhelm. Woodcock sought the investigation after critics said some of the interactions were too cozy.
https://www.bloomberg.com/news/articles/2021-...ioner-post?
Acting FDA Commissioner Janet Woodcock has reportedly been ruled out as a nominee for the agency's permanent position, according to sources familiar with the matter. Controversy over the FDA's approval of Biogen's Alzheimer's disease drug Aduhelm may have affected Woodcock's prospects of being nominated as permanent FDA chief.
" Woodcock, 72, who has been at the FDA for 35 years, declined to comment.
"The Department of Health and Human Services Office of Inspector General also said earlier this month it would examine the FDA’s use of an approval process intended to grant speedier access to experimental medicines, which the agency used for Aduhelm.
The office said as part of the probe it would look into concerns raised about contacts between FDA and Biogen officials before the clearance of Aduhelm. Woodcock sought the investigation after critics said some of the interactions were too cozy.
https://www.bloomberg.com/news/articles/2021-...ioner-post?
(2)
(0)Scroll down for more posts ▼
